NUTF2

Nuclear transport factor 2 · P61970 · NUTF2 on Sugi Atlas →

0 patent compounds predicted against NUTF2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NUTF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants PHASE1/PHASE2SUSPENDED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients PHASE1/PHASE2COMPLETED
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer PHASE2UNKNOWN
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Concentration and Activity of Lapatinib in Vestibular Schwannomas EARLY_PHASE1COMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Screening for Hepatitis Virus B Protein X (HBx) in Colitis-associated Cancer (CAC) nanNOT_YET_RECRUITING
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Family Study of Head and Neck Cancers in Taiwan nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NUTF2 binder may also engage these)

ProteinNameSimilarity
Q5R8G4 1.000 Q5R8G4 →
Q32KP9 1.000 Q32KP9 →
P61972 1.000 P61972 →
P61971 1.000 P61971 →
O42242 0.985 O42242 →
Q96VN3 0.968 Q96VN3 →
Q9C7F5 0.966 Q9C7F5 →
Q9FZK4 0.960 Q9FZK4 →
Q2KIW0 0.950 Q2KIW0 →
Q6FRC6 0.949 Q6FRC6 →
P33331 0.948 P33331 →
Q75AA5 0.946 Q75AA5 →
Q6CQX4 0.946 Q6CQX4 →
Q9UKK6 0.937 Q9UKK6 →
Q9QZV9 0.935 Q9QZV9 →
Q10100 0.930 Q10100 →
B2GV77 0.927 B2GV77 →
Q3UNA4 0.927 Q3UNA4 →
Q8NJ52 0.927 Q8NJ52 →
Q9NPJ8 0.921 Q9NPJ8 →
A6QNX3 0.912 A6QNX3 →
Q6CC82 0.910 Q6CC82 →
P87102 0.907 P87102 →
Q5ZLH0 0.895 Q5ZLH0 →
VAMP7 Vesicle-associated membrane protein 7 0.894 landscape →
Q5RF94 0.893 Q5RF94 →
Q5E964 0.892 Q5E964 →
Q2RAK2 0.889 Q2RAK2 →
Q17QI5 0.888 Q17QI5 →
Q9JHW5 0.888 Q9JHW5 →